Physician profile
Kerry B Struttmann
NPI 1336781343
$614.01
in general payments reported to CMS, 2019-2025
14 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.35 · 2022: $67.76 · 2023: $127 · 2024: $285 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $96.81 | 2022-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $67.35 | 2021-2024 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $64.64 | 2022-2025 | Rexulti |
| Abbvie INC. | $63.63 | 2024-2025 | |
| Lilly USA, LLC | $62.85 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $43.46 | 2024 | Breztri |
| Exact Sciences Corporation | $40.34 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $37.22 | 2023-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Pfizer INC. | $32.16 | 2024 | |
| Dexcom, INC. | $26.38 | 2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $23.51 | 2024 | Tymlos |
| Mylan Specialty L.P. | $22.30 | 2023 | Yupelri |
| Astellas Pharma US INC | $20.26 | 2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Struttmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.